(3,4-Dimethoxyphenyl)acetic acid, also known as homoveratric acid, is a naturally occurring organic compound found in various plants. It is a precursor to several important pharmaceutical compounds, including the antipsychotic drug haloperidol and the anti-inflammatory drug ibuprofen. It is studied for its potential medicinal properties, such as its anti-inflammatory and anti-cancer effects. It is also used as a building block in the synthesis of other organic compounds.'
(3,4-dimethoxyphenyl)acetic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
homoveratric acid : A phenylacetic acid substituted at positions 3 and 4 by methoxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7139 |
| CHEBI ID | 86655 |
| SCHEMBL ID | 153055 |
| MeSH ID | M0525424 |
| Synonym |
|---|
| EU-0066571 |
| AC-15716 |
| BB 0248998 |
| (3,4-dimethoxy-phenyl)-acetic acid |
| ksc-11-262-2 |
| KUC108679N |
| 3,4-(dimethoxy)benzeneacetic acid |
| acetic acid,4-dimethoxyphenyl)- |
| homoveratric acid |
| 93-40-3 |
| 3,4-(dimethoxyphenyl) acetic acid |
| (3,4-dimethoxyphenyl)acetic acid |
| benzeneacetic acid,4-dimethoxy- |
| nsc2753 |
| nsc-2753 |
| acetic acid, (3,4-dimethoxyphenyl)- |
| benzeneacetic acid, 3,4-dimethoxy- |
| CHEMDIV3_014360 |
| nsc-27897 |
| nsc27897 |
| 3,4-dimethoxybenzeneacetic acid |
| brn 1110282 |
| ai3-23354 |
| 3,4-dimethoxyphenyl acetic acid |
| einecs 202-244-5 |
| nsc 2753 |
| 3,4-dimethoxyphenylacetic acid |
| IDI1_030158 |
| AK-968/41169417 |
| STK299264 |
| inchi=1/c10h12o4/c1-13-8-4-3-7(6-10(11)12)5-9(8)14-2/h3-5h,6h2,1-2h3,(h,11,12 |
| 3,4-dimethoxyphenylacetic acid, 98% |
| H-3300 |
| D0640 |
| 2-(3,4-dimethoxyphenyl)acetic acid |
| BMSE000682 |
| HMS1513M16 |
| AKOS000119394 |
| unii-yy50git3c7 |
| yy50git3c7 , |
| 2-(3,4-dimethoxyphenyl)aceticacid |
| (3,4-dimethoxyphenyl) acetic acid |
| S3961 |
| FT-0612084 |
| AM20060235 |
| SCHEMBL153055 |
| DTXSID5059086 |
| alpha-(3,4-dimethoxyphenyl)acetic acid |
| 3,4-dimethoxyphenyl-acetic acid |
| 3,4-dimethoxy-phenylacetic acid |
| acetic acid, 3,4-dimethoxyphenyl- |
| 3,4-dimethoxyphenylaceticacid |
| Z56924495 |
| BS-4085 |
| mfcd00004335 |
| 3,4-dimethyloxy phenyl acetic acid |
| F0902-7631 |
| homoveratrumic acid |
| SR-01000596943-1 |
| sr-01000596943 |
| homoveratric acid, vetec(tm) reagent grade, 98% |
| CS-W020108 |
| 3,4-dimethoxyphenylacetate |
| homoveratrate |
| (3,4-dimethoxyphenyl)acetate |
| 3,4-dimethoxybenzeneacetate |
| HY-Y0771 |
| SY006121 |
| Q10395556 |
| CHEBI:86655 |
| 2-(3,4-dimethoxyphenyl)ethanoic acid |
| CCG-266554 |
| homovaretic acid |
| EN300-17388 |
| (3,4-dimethoxyphenyl)acetic acid(homoveratric acid) |
| Role | Description |
|---|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dimethoxybenzene | Any methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives. |
| phenylacetic acids | Any monocarboxylic acid that is phenylacetic acid or its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||